SET welcomes medical equipment manufacturer and distributor “NAM”

Editorial Staff

SET welcomes medical equipment manufacturer and distributor “NAM” this October 31

The Stock Exchange of Thailand (SET) lists Namwiwat Medical Corporation pcl, a leading manufacturer, importer, and distributor of consumer products industry group, personal products & pharmaceuticals sector on October 31, under the ticker symbol "NAM".

The company has a market capitalization at its initial public offering (IPO) of 5.39 billion baht (approx. USD 149.18 million).

SET senior executive vice president Manpong Senanarong said that NAM will be listed and start trading on SET in the consumer products industry group, personal products & pharmaceuticals sector.

NAM manufactures, imports and distributes medical devices and equipment for the cleaning, disinfection and sterilization of medical equipment in hospitals and healthcare centers in compliance with public health standards.

NAM also produces and distributes consumable products for use with cleaning, disinfection and sterilization tools for medical equipment. The company’s production processes meet international standards, which are on par with American and European quality standards.

NAM has developed proprietary patented medical innovations and has key customer base of over 1,200 hospitals and public health organizations both domestically and internationally.

After IPO, NAM has a paid-up capital of 350 million baht with a par value of 0.50 baht each. It offered 181 million IPO shares, consisting of 105 million newly issued shares and 76 million existing common shares held by WAI Global Corporation, to individuals at the underwriters’ discretion, patrons, directors, executives, and employees of the company, during October 19 - 24, 2023 at 7.70 baht each, raising a total of 808.50 million baht.

Finnex Advisory Co and Thanachart Securities pcl are the financial advisors, and Finansa Securities is the lead underwriter.

NAM chief executive officer Viroj Chaiturdkiet said that NAM aims to create new products and services based on the company’s innovations from inventions and R&D to expand distribution channels both locally and globally, and to diversify the customer base originally from medical organizations to other groups, such as laboratories, clinics, laboratories (human and animal), medical service providers, and households.

After the IPO, the company's major shareholders are the Chaiturdkiet group (the founding group) (59.14 %) and Innobic LL Holding Co(a company under PTT group) (15 %).